Search
AEG35156
go.drugbank.com/drugs/DB06184InvestigationalAEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. … This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis.
DTX-101
go.drugbank.com/drugs/DB17699InvestigationalIt was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103] … DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.
SCY-635
go.drugbank.com/drugs/DB12451InvestigationalSCY-635 has been investigated for the treatment of Chronic Hepatitis C and Hepatitis C Infection.
Biropepimut-S
go.drugbank.com/drugs/DB14816InvestigationalBiropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral
Peldesine
go.drugbank.com/drugs/DB02568InvestigationalPeldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.
Categories: N-Glycosyl Hydrolases, antagonists & inhibitorsICG-136
go.drugbank.com/drugs/DB17343ExperimentalICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Mocetinostat
go.drugbank.com/drugs/DB11830InvestigationalMocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.
Bacillus calmette-guerin substrain tokyo 172-1 live antigen
go.drugbank.com/drugs/DB14968InvestigationalBacillus calmette-guerin substrain tokyo 172-1 live antigen is under investigation in clinical trial NCT03091660 (S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive
LY3884961
go.drugbank.com/drugs/DB17070InvestigationalLY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]
MBP-091
go.drugbank.com/drugs/DB17741ExperimentalMBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]